5 Things NPs and PAs Need to Know About Tardive Dyskinesia

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Systemic Lupus Erythematosus

Current Management and Future Options for Tardive Dyskinesia

Clinical Trials in IBD.

New Psoriasis Treatments

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Making Decisions With Your Osteoarthritis Patients

Advances in Managing Inhibitors in Patients With Hemophilia A

Essential Updates in Atopic Dermatitis:

Management of Drug-Induced Movement Disorders: Focus on Tardive Dyskinesia.

Progression After Cancer Immunotherapy in Advanced NSCLC

Understanding the Many Faces of Pseudobulbar Affect

Ask the Onychomycosis Expert, Part 2

Ask the Onychomycosis Expert, Part 1

Epidemiology Venous Pathophysiology Etiology.

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

Case Challenges in Chronic Migraine

Updates in Management of Atopic Dermatitis From Real Patient Cases

Advances in Dry Eye.

Before and After: Patient Cases in Onychomycosis

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Chronic Idiopathic Urticaria

Asthma and Atopic Comorbidities

The Evolving Role of Immunotherapy in NSCLC

Multidisciplinary Perspectives on Interstitial Lung Diseases

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Hyperhidrosis Is Burdensome!

Gene Therapy: Past, Present, and Future

Tackling Atopic Dermatitis

Ask the Experts.

Immunotherapy for cSCC

Novel Approaches in T1D Management

Perspectives on the Impact of Inflammation in OA

Insights Into the Spectrum of Tardive Dyskinesia

Impactful Data in TD That Can Guide Treatment Decisions

Updates in Neurogenic Orthostatic Hypotension

Best Practices in the Clinical Management of Motor Symptoms Associated With Huntington Disease.

New Recommendations on How to Stage Hidradenitis Suppurativa

When Is Biologic Therapy Appropriate for HS?

Oral Prostanoids and PAH

Parkinson Disease Psychosis

Talking With Your Patients About Excessive Sweating

Getting to Grips With the Science of CGRP and Migraine

Scientific Update.

Guide to Atopic Dermatitis

Are We Making Progress in the Management of Huntington Disease?

Optimizing Joint Health in Hemophilia

The Psychiatrist's Role in Tardive Dyskinesia

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Novel Concepts in the Management of RCC

Improving Overall Health

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Psychiatrist's Role in Tardive Dyskinesia

The ABCs of Diagnosing Tardive Dyskinesia

Getting PPG Under Control

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Tardive Dyskinesia 101.

Merging the Art and Science of Managing nOH in Clinical Practice

Immune Checkpoint Inhibitors in Lung Cancer

Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders.

Management of Drug-Induced Movement Disorders: Focus on Tardive Dyskinesia.

Motor Fluctuations in PD

Presentation transcript:

5 Things NPs and PAs Need to Know About Tardive Dyskinesia

This program will include a discussion of off-label treatments not approved by the FDA for use in the US.

Tardive Dyskinesia

Clinical Presentation of Tardive Dyskinesia

Videos of Patients With Tardive Dyskinesia

Subtypes of TD

Diagnosis: Clinical Signs and Symptoms

Diagnosis: AIMS

Scoring the AIMS Procedure and Examples of Movements

Scoring the AIMS Global Judgments and Dental Status

Pathophysiology of TD

Prevalence of TD

Risk Factors

Prevent Onset and Minimize Risk

Treatment of TD Agents Used Prior to 2017

Vesicular Monoamine Transporter 2 Inhibitors

Tetrabenazine

Deutetrabenazine

AIM-TD: Deutetrabenazine

Valbenazine

KINECT 3: Valbenazine

Updated AAN Treatment Algorithm

Monitoring Patients on VMAT Inhibitors

Role of Physician Assistants and Nurse Practitioners in TD Management

Practice Pearls for Managing TD

Concluding Remarks

Abbreviations

Abbreviations (cont)